Is Vaxfab Enterp. overvalued or undervalued?

As of 3 October 2025, Vaxfab Enterprises has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company is currently considered undervalued, with a PE ratio of 28.38, an EV to EBITDA of 27.60, and a Price to Book Value of 2.11. These ratios suggest that the stock is priced favorably compared to its earnings and book value.
In comparison to its peers, Vaxfab's valuation appears more reasonable, especially when contrasted with Elitecon International, which has a PE ratio of 401.35, and MMTC, which has a PE ratio of 147.49. While Vaxfab's PEG ratio stands at 0.00, indicating no growth expectations priced in, it is significantly lower than many of its peers, reinforcing its undervalued status. Notably, Vaxfab has outperformed the Sensex significantly over the past year, with a return of 328.26% compared to the Sensex's decline of 1.56%, further supporting the attractiveness of its current valuation.